

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bell et al.

Serial No.: To Be Assigned Group Art Unit:

File Date: Concurrently Herewith Examiner:

For: Phenylalkanoic Acid And Phenylalkoxyalkanoic Acid Derivatives As HPPAR Activators

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed:
- ☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
- ☒ A copy of the International Search Report which issued on International Application No. PCT/EP03/06415 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

Robert H. Brink
Robert H. Brink
Registration No. 36,094

Date: 17 December 2004
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-3323
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG4798USW		SERIAL NO. To Be Assigned 10751867	
				APPLICANT: Bell et al.			
				FILING DATE: Concurrently Herewith		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
		4,221,919	Sept. 9, 1980	Grimova, et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
		WO 99/11255	Mar. 11, 1999	WIPO			
		WO 00/64876	Nov. 2, 2000	WIPO			
		EP 1067109	Jan. 10, 2001	EUROPE			
		WO 97/31907	Sept. 4, 1997	WIPO			
		EP 1132376	Sept. 12, 2001	EUROPE			
		EP 1283039	Feb. 12, 2003	EUROPE			
		WO 01/36351	May 25, 2001	WIPO			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
		Gentles, R.G., et al. "Standardization Protocols and Optimized Precursor Sets For The Efficient Application of Automated Parallel Synthesis to Lead Optimization: A Mitsunobu Example." Journal of Combinatorial Chemistry (2002), 4(5), pgs. 442-456.					
		Kuchar, M., et al. "Benzyloxyarylalipatic Acids: Synthesis and Quantitative Relations Between Structure and Antiinflammatory Activity." Collection of Czechoslovak Chemical Communications, Academic Press, London, GB, vol. 47, 1982, pgs 2514-2524.					
		Kuchar, M., et al. "The Effects of Lipophilicity on the Inhibition of Denaturation of Serum Albumin and on the Activation of Fibrinolysis Observed With Aseries of Benzyloxyarylalipatic Acids." Collection of Czechoslovak Chemical Communications, Academic Press, London, GB, vol. 48, 1983, pgs 1077-1088.					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							